- Q1 2024 Heron Therapeutics Inc Earnings Call TranscriptMay 07, 2024€2.85 (+10.71%)Earnings
- Q4 2023 Heron Therapeutics Inc Earnings Call TranscriptMar 12, 2024€2.16 (-7.69%)Earnings
- Q3 2023 Heron Therapeutics Inc Earnings Call TranscriptNov 14, 2023€0.525 (-6.25%)Earnings
- Q2 2023 Heron Therapeutics Inc Earnings Call TranscriptAug 14, 2023€1.46 (-0.68%)Earnings
- Q1 2023 Heron Therapeutics Inc Earnings Call TranscriptMay 11, 2023€2.08 (-5.45%)Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 20, 2023
- Q4 2022 Heron Therapeutics Inc Earnings Call TranscriptMar 23, 2023€1.9 (-0.06%)Earnings
- Q3 2022 Heron Therapeutics Inc Earnings Call TranscriptNov 08, 2022€3.37 (+1.05%)Earnings
- Heron Therapeutics Inc Investor Call TranscriptSep 19, 2022
- Q2 2022 Heron Therapeutics Inc Earnings Call TranscriptAug 09, 2022€4.18 (+20.54%)Earnings
- Q1 2022 Heron Therapeutics Inc Earnings Call TranscriptMay 09, 2022€3.81 (+1.18%)Earnings
- Heron Therapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Q4 2021 Heron Therapeutics Inc Earnings Call TranscriptFeb 28, 2022€6.28 (-5.54%)Earnings
- Heron Therapeutics Inc Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF TranscriptDec 09, 2021
- Q3 2021 Heron Therapeutics Inc Earnings Call TranscriptNov 03, 2021€9.69 (-0.23%)Earnings
- Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEFâ„¢ - Conference Call TranscriptMay 13, 2021
- Heron Therapeutics Inc 2020 Conference Call TranscriptJun 29, 2020
- Heron Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2020
- Heron Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptOct 02, 2019
- Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 14, 2019
- Heron Therapeutics Inc to discuss the Complete Response Letter - Conference Call TranscriptMay 01, 2019
Q4 2023 Heron Therapeutics Inc Earnings Call Transcript
Thank you for standing by, and welcome to the Heron Therapeutics Fourth Quarter 2023 conference call. I would now like to welcome Melissa Duran, Executive Director, legal to begin the call. Melissa, over to you.
Thank you, operator, and good afternoon, everyone. Thank you for joining us on the Heron Therapeutics conference call this afternoon to discuss the Company's financial results for the fourth quarter ended December 31st, 2023.
With me today from hereon are Craig Collard, Chief Executive Officer, here at Workday, Executive Vice President, Chief Financial Officer, Bill Forbes, Executive Vice President, Chief Development Officer, and Kevin Werner, Senior Vice President, Medical Affairs strategy. For those of you participating via conference call, Pfizer made available via webcast and can also be accessed via the Investor Relations page of our website following the conclusion of today's call.
Before we begin, let me quickly remind you that during the course of this conference call, the Company will make forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)